Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(18.3%),OrbiMed Israel GP Ltd.(18.3%), etc.
Chemomab Therapeutics | SC 13D/A：超过5%持股股东披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(18.3%),OrbiMed Israel GP Ltd.(18.3%)等
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。